Buchanan, Robert W <br/><br/>
A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia.  [electronic resource] 

 -  Schizophrenia bulletin  Jan 2005 
 - 5-19 p.  digital 
<br/><br/> Publication Type: Congress; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S. 
<br/><br/><label>ISSN: </label>0586-7614 
<br/><br/><label>Standard No.: </label>10.1093/schbul/sbi020  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antipsychotic Agents<br/>Brief Psychiatric Rating Scale<br/>Clinical Trials as Topic--standards<br/>Cognition Disorders--diagnosis<br/>Combined Modality Therapy<br/>Guidelines as Topic<br/>Health Promotion<br/>Humans<br/>Mental Health Services--standards<br/>National Institute of Mental Health (U.S.)<br/>Polypharmacy<br/>Psychotherapy<br/>Schizophrenia--complications<br/>Severity of Illness Index<br/>Treatment Outcome<br/>United States<br/>United States Food and Drug Administration